OVERALL SURVIVAL WITH NIVOLUMAB FOR PATIENTS WITH ADVANCED, PREVIOUSLY TREATED RENAL CELL CARCINOMA

被引：0
|
作者：
Sullivan, W. [1 ]
Lee, D. [1 ]
Willis, A. [1 ]
Doan, J. [2 ]
Gooden, K. [2 ]
Sowdani, A. [3 ]
机构：
[1] BresMed Hlth Solut, Sheffield, S Yorkshire, England
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN52
引用
收藏
页码：A96 / A96
页数：1
相关论文
共 50 条
  • [31] Nivolumab in the treatment of advanced renal cell carcinoma
    Arasaratnam, Malmaruha
    Gurney, Howard
    FUTURE ONCOLOGY, 2018, 14 (17) : 1679 - 1689
  • [32] Nivolumab in the treatment of advanced renal cell carcinoma
    Tomczak, Piotr
    Synowiec, Zuzanna
    ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (02): : 124 - 126
  • [33] Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab
    Ueda, Kosuke
    Suekane, Shigetaka
    Kurose, Hirofumi
    Ogasawara, Naoyuki
    Hiroshige, Tasuku
    Chikui, Katsuaki
    Uemura, Keiichiro
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Matsuo, Mitsunori
    Igawa, Tsukasa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (02) : 179 - 186
  • [34] ROLE OF PRIMARY TUMOR IN ADVANCED RENAL CELL CARCINOMA (RCC) PATIENTS TREATED WITH NIVOLUMAB/IPILIMMUMAB OR CABOZANTINIB
    Ciccarese, Chiara
    Maruzzo, Marco
    Atzori, Francesco
    Galli, Luca
    Scagliarini, Sarah
    Massari, Francesco
    Verzoni, Elena
    Cannella, Maria Antonella
    Maratta, Maria Grazia
    Astore, Serena
    Caserta, Claudia
    Bimabatti, Davide
    Deppieri, Filippo Maria
    Dessi, Mariele
    Paolieri, Federico
    Riccardi, Ferdinando
    Bracarda, Sergio
    De Giorgi, Ugo
    Basso, Umberto
    Procopio, Giuseppe
    Tortora, Giampaolo
    ANTICANCER RESEARCH, 2021, 41 (10) : 5309 - 5312
  • [35] Impact of Comorbidity on Overall Survival in Patients Surgically Treated for Renal Cell Carcinoma Editorial Comment
    Marshall, Fray F.
    JOURNAL OF UROLOGY, 2009, 181 (05): : 2061 - 2061
  • [36] Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214
    Gruenwald, V.
    Choueiri, T. K.
    Rini, B. I.
    Powles, T.
    George, S.
    Grimm, M-O.
    McHenry, M. B.
    Maurer, M.
    Motzer, R. J.
    Hammers, H. J.
    Tannir, N. M.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 382 - +
  • [37] Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma
    Kobayashi, Y.
    Arai, H.
    Honda, M.
    CURRENT ONCOLOGY, 2020, 27 (04) : 225 - 228
  • [38] EARLY-ONSET HYPOTHYROIDISM AND SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH FIRST-LINE SUNITINIB: UPDATED OVERALL SURVIVAL DATA
    Pinto, A.
    Garrido, M.
    Cruz, P.
    Lopez, D.
    Zambrana, F.
    Aguayo, C.
    Feliu, J.
    Espinosa, E.
    ANNALS OF ONCOLOGY, 2014, 25
  • [39] A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma
    Kimura, Michio
    Usami, Eiseki
    Teramachi, Hitomi
    Yoshimura, Tomoaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 12 (03) : 284 - 289
  • [40] ADVANCED RENAL CELL CARCINOMA IN PREVIOUSLY TREATED PATIENTS: MEASURING HEALTHCARE USE, PRODUCTIVITY LOSS AND COSTS
    Sousa, G.
    Mansinho, H.
    Figueiredo, A.
    Fraga, A.
    Sousa, N.
    VALUE IN HEALTH, 2016, 19 (07) : A611 - A611
12345